Editas Medicine, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
EDIT Nasdaq 2836 www.editasmedicine.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Editas Medicine, Inc.

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks? - Sep 23rd, 2026 3:49 pm
Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls - Sep 23rd, 2026 7:49 am
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon - Sep 23rd, 2026 6:22 am
Editas Medicine Targets 2026 Patient Dosing for LDL Gene-Editing Therapy - Sep 11th, 2026 7:01 pm
Editas Medicine Reports Inducement Grants to New Chief Medical Officer - Sep 9th, 2026 7:00 am
Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401 - Sep 9th, 2026 5:02 am
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer - Sep 8th, 2026 5:00 am
Editas (EDIT) Up 6.2% Since Last Earnings Report: Can It Continue? - Sep 4th, 2026 9:30 am
Editas Medicine to Participate in Upcoming Investor Conferences - Sep 1st, 2026 7:00 am
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains - Aug 24th, 2026 7:59 am
Moderna’s Newfound War Chest Opens Door for 4 Strategic Acquisition Targets - Aug 20th, 2026 5:35 am
Is Editas Medicine (EDIT) Outperforming Other Medical Stocks This Year? - Aug 10th, 2026 7:40 am
EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus - Aug 6th, 2026 9:26 am
Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates - Aug 5th, 2026 4:10 pm
Editas Medicine Announces Second Quarter 2026 Results and Business Updates - Aug 5th, 2026 2:01 pm
Geron (GERN) Reports Q2 Loss, Beats Revenue Estimates - Aug 5th, 2026 7:00 am
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D. - Aug 4th, 2026 2:15 pm
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report? - Jun 4th, 2026 9:30 am
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? - May 31st, 2026 10:31 am